Anna-Karin Hamberg

Model-informed precision dosing of vancomycin in clinical practice: an intervention development study

Swartling, Maria; Hamberg, Anna-Karin; Furebring, Mia; Tängdén, Thomas et al.

Part of International Journal of Clinical Pharmacy, p. 178-186, 2025

• DOI for Model-informed precision dosing of vancomycin in clinical practice: an intervention development study
• Download full text (pdf) of Model-informed precision dosing of vancomycin in clinical practice: an intervention development study

Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events

Attelind, Sofia; Hallberg, Pär; Wadelius, Mia; Hamberg, Anna-Karin et al.

Part of Frontiers in Genetics, 2022

• DOI for Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events
• Download full text (pdf) of Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events

General clinical and methodological considerations on the extrapolation of pharmacokinetics and optimization of study protocols for small molecules and monoclonal antibodies in children

Bouazza, Naim; Dokoumetzidis, Aristides; Knibbe, Catherijne A. J.; de Wildt, Saskia N. et al.

Part of British Journal of Clinical Pharmacology, p. 4985-4996, 2022

• DOI for General clinical and methodological considerations on the extrapolation of pharmacokinetics and optimization of study protocols for small molecules and monoclonal antibodies in children

CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis

Takeuchi, Masanobu; Kobayashi, Tohru; Biss, Tina; Kamali, Farhad et al.

Part of The Pharmacogenomics Journal, p. 306-319, 2020

• DOI for CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis

Effect of CYP2C9, VKORC1, and CYP4F2 on warfarin maintenance dose in children aged less than 18 year of age: systematic review and meta-analysis

Takeuchi, M.; Kobayashi, T.; Biss, T.; Kamali, F. et al.

Part of Clinical Pharmacology and Therapeutics, 2018

• DOI for Effect of CYP2C9, VKORC1, and CYP4F2 on warfarin maintenance dose in children aged less than 18 year of age: systematic review and meta-analysis

Model-informed precision dosing of vancomycin in clinical practice: an intervention development study

Swartling, Maria; Hamberg, Anna-Karin; Furebring, Mia; Tängdén, Thomas et al.

Part of International Journal of Clinical Pharmacy, p. 178-186, 2025

• DOI for Model-informed precision dosing of vancomycin in clinical practice: an intervention development study
• Download full text (pdf) of Model-informed precision dosing of vancomycin in clinical practice: an intervention development study

Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events

Attelind, Sofia; Hallberg, Pär; Wadelius, Mia; Hamberg, Anna-Karin et al.

Part of Frontiers in Genetics, 2022

• DOI for Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events
• Download full text (pdf) of Genetic determinants of apixaban plasma levels and their relationship to bleeding and thromboembolic events

Effect of CYP2C9, VKORC1, and CYP4F2 on warfarin maintenance dose in children aged less than 18 year of age: systematic review and meta-analysis

Takeuchi, M.; Kobayashi, T.; Biss, T.; Kamali, F. et al.

Part of Clinical Pharmacology and Therapeutics, 2018

• DOI for Effect of CYP2C9, VKORC1, and CYP4F2 on warfarin maintenance dose in children aged less than 18 year of age: systematic review and meta-analysis

Is Trough Concentration of Vancomycin Predictive of the Area Under the Curve?: A Commentary

Hamberg, Anna-Karin; Keizer, Ron

Part of Therapeutic Drug Monitoring, p. 303-303, 2017

• DOI for Is Trough Concentration of Vancomycin Predictive of the Area Under the Curve?: A Commentary

A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children

Hamberg, Anna-Karin; Hellman, Jacob; Dahlberg, Jonny; Jonsson, E Niclas et al.

Part of BMC Medical Informatics and Decision Making, 2015

• DOI for A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children
• Download full text (pdf) of A Bayesian decision support tool for efficient dose individualization of warfarin in adults and children

Characterising variability in warfarin dose requirements in children using modelling and simulation

Hamberg, Anna-Karin; Wadelius, Mia; Friberg, Lena E; Biss, Tina T et al.

Part of British Journal of Clinical Pharmacology, p. 158-169, 2013

• DOI for Characterising variability in warfarin dose requirements in children using modelling and simulation

Warfarin dose prediction in children using pharmacometric bridging: comparison with published pharmacogenetic dosing algorithms

Hamberg, Anna-Karin; Friberg, Lena E; Hanséus, Katarina; Ekman-Joelsson, Britt-Marie et al.

Part of European Journal of Clinical Pharmacology, p. 1275-1283, 2013

• DOI for Warfarin dose prediction in children using pharmacometric bridging: comparison with published pharmacogenetic dosing algorithms
• Download full text (pdf) of Warfarin dose prediction in children using pharmacometric bridging: comparison with published pharmacogenetic dosing algorithms

Warfarin dose prediction in children using pharmacogenetics information

Biss, Tina; Hamberg, Anna-Karin; Avery, Peter; Wadelius, Mia et al.

Part of British Journal of Haematology, p. 106-109, 2012

• DOI for Warfarin dose prediction in children using pharmacogenetics information

A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy

Avery, P. J.; Jorgensen, A.; Hamberg, Anna-Karin; Wadelius, Mia et al.

Part of Clinical Pharmacology and Therapeutics, p. 701-706, 2011

• DOI for A Proposal for an Individualized Pharmacogenetics-Based Warfarin Initiation Dose Regimen for Patients Commencing Anticoagulation Therapy

A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age

Hamberg, Anna-Karin; Wadelius, Mia; Lindh, J. D.; Dahl, Marja- Liisa et al.

Part of Clinical Pharmacology and Therapeutics, p. 727-734, 2010

• DOI for A Pharmacometric Model Describing the Relationship Between Warfarin Dose and INR Response With Respect to Variations in CYP2C9, VKORC1, and Age

Predicting the relative importance of genetic, clinical and demographic factors on warfarin dose in children using pharmacometric modelling

Hamberg, Anna-Karin; Wadelius, Mia; Friberg, Lena E; Biss, Tina T et al.

General clinical and methodological considerations on the extrapolation of pharmacokinetics and optimization of study protocols for small molecules and monoclonal antibodies in children

Bouazza, Naim; Dokoumetzidis, Aristides; Knibbe, Catherijne A. J.; de Wildt, Saskia N. et al.

Part of British Journal of Clinical Pharmacology, p. 4985-4996, 2022

• DOI for General clinical and methodological considerations on the extrapolation of pharmacokinetics and optimization of study protocols for small molecules and monoclonal antibodies in children

CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis

Takeuchi, Masanobu; Kobayashi, Tohru; Biss, Tina; Kamali, Farhad et al.

Part of The Pharmacogenomics Journal, p. 306-319, 2020

• DOI for CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis

Pharmacogenetics-based warfarin dosing in children

Hamberg, Anna-Karin; Wadelius, Mia

Part of Pharmacogenomics (London), p. 361-374, 2014

• DOI for Pharmacogenetics-based warfarin dosing in children

Pharmacometric Models for Individualisation of Warfarin in Adults and Children

Hamberg, Anna-Karin

2013

• Download full text (pdf) of Pharmacometric Models for Individualisation of Warfarin in Adults and Children